132 related articles for article (PubMed ID: 1831937)
1. Complement fragment C4d and Bb levels in inflammatory skin diseases (e.g. SLE, atopic dermatitis, erythroderma and pustulosis palmaris et plantaris) for assessment of complement activation.
Takematsu H; Tagami H
Tohoku J Exp Med; 1991 Apr; 163(4):263-8. PubMed ID: 1831937
[TBL] [Abstract][Full Text] [Related]
2. Activation of the alternative pathway of complement in psoriatic lesional skin.
Takematsu H; Tagami H
Dermatologica; 1990; 181(4):289-92. PubMed ID: 2073958
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity.
Manzi S; Rairie JE; Carpenter AB; Kelly RH; Jagarlapudi SP; Sereika SM; Medsger TA; Ramsey-Goldman R
Arthritis Rheum; 1996 Jul; 39(7):1178-88. PubMed ID: 8670328
[TBL] [Abstract][Full Text] [Related]
4. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy.
Buyon JP; Tamerius J; Ordorica S; Young B; Abramson SB
Arthritis Rheum; 1992 Jan; 35(1):55-61. PubMed ID: 1731815
[TBL] [Abstract][Full Text] [Related]
5. Preferential activation of the alternative pathway of complement in psoriatic lesional skin.
Takematsu H; Tagami H
Dermatology; 1992; 184(2):159-60. PubMed ID: 1498383
[No Abstract] [Full Text] [Related]
6. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement.
Buyon JP; Tamerius J; Belmont HM; Abramson SB
Arthritis Rheum; 1992 Sep; 35(9):1028-37. PubMed ID: 1418018
[TBL] [Abstract][Full Text] [Related]
7. Complement activation in patients with systemic lupus erythematosus without nephritis.
Mollnes TE; Haga HJ; Brun JG; Nielsen EW; Sjöholm A; Sturfeldt G; Mårtensson U; Bergh K; Rekvig OP
Rheumatology (Oxford); 1999 Oct; 38(10):933-40. PubMed ID: 10534542
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the activation pathways of the complement in psoriatic patients by use of complement fragment C4d and Bb measurements.
Takematsu H; Tagami H
Dermatologica; 1989; 179 Suppl 1():16-9. PubMed ID: 2789155
[TBL] [Abstract][Full Text] [Related]
9. Complement activation during painful crisis in sickle cell anemia.
Mold C; Tamerius JD; Phillips G
Clin Immunol Immunopathol; 1995 Sep; 76(3 Pt 1):314-20. PubMed ID: 7554454
[TBL] [Abstract][Full Text] [Related]
10. Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus.
Senaldi G; Makinde VA; Vergani D; Isenberg DA
Ann Rheum Dis; 1988 Nov; 47(11):913-7. PubMed ID: 3264693
[TBL] [Abstract][Full Text] [Related]
11. Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis.
Brodeur JP; Ruddy S; Schwartz LB; Moxley G
Arthritis Rheum; 1991 Dec; 34(12):1531-7. PubMed ID: 1747138
[TBL] [Abstract][Full Text] [Related]
12. Elevated levels of iC3b and C4d, but not Bb, complement fragments from plasma of persons infected with human T cell leukemia virus (HTLV) with HTLV-I-associated myelopathy/tropical spastic paraparesis.
Saarloos MN; Koenig RE; Spear GT
J Infect Dis; 1995 Oct; 172(4):1095-7. PubMed ID: 7561187
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of detection of complement activation products in evaluating SLE activity.
Nagy G; Brózik M; Varga L; Füst G; Kirschfink M; Kiss E; Gergely P
Lupus; 2000; 9(1):19-25. PubMed ID: 10713643
[TBL] [Abstract][Full Text] [Related]
14. Ba and Bb fragments of factor B activation: fragment production, biological activities, neoepitope expression and quantitation in clinical samples.
Kolb WP; Morrow PR; Tamerius JD
Complement Inflamm; 1989; 6(3):175-204. PubMed ID: 2472921
[TBL] [Abstract][Full Text] [Related]
15. Complement activation in severe Plasmodium falciparum malaria.
Wenisch C; Spitzauer S; Florris-Linau K; Rumpold H; Vannaphan S; Parschalk B; Graninger W; Looareesuwan S
Clin Immunol Immunopathol; 1997 Nov; 85(2):166-71. PubMed ID: 9344699
[TBL] [Abstract][Full Text] [Related]
16. Influence of C4 null alleles on C4 activation in systemic lupus erythematosus.
Briggs DC; Senaldi G; Isenberg DA; Welsh KI; Vergani D
Ann Rheum Dis; 1991 Apr; 50(4):251-4. PubMed ID: 2029208
[TBL] [Abstract][Full Text] [Related]
17. Classical complement activation induced by pregnancy: implications for management of connective tissue diseases.
Hopkinson ND; Powell RJ
J Clin Pathol; 1992 Jan; 45(1):66-7. PubMed ID: 1740520
[TBL] [Abstract][Full Text] [Related]
18. Generation of the membrane attack complex during haemodialysis: impact of classical and alternative pathway components.
Hauser AC; Derfler K; Stockenhuber F; Janata O; Balcke P
Clin Sci (Lond); 1990 Nov; 79(5):471-6. PubMed ID: 2174314
[TBL] [Abstract][Full Text] [Related]
19. Alternative pathway of complement is activated during in vitro ventricular assist.
Chen JC; Huynh TN; Serna DL; Sun CP; Ha H; Steward E; Webster S; Brenner M
J Investig Med; 1999 Nov; 47(9):502-6. PubMed ID: 10572381
[TBL] [Abstract][Full Text] [Related]
20. Alterations in C3, C4, factor B, and related metabolites in septic shock.
Lin RY; Astiz ME; Saxon JC; Saha DC; Rackow EC
Clin Immunol Immunopathol; 1993 Nov; 69(2):136-42. PubMed ID: 8403550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
